Can oral infection be a risk factor for Alzheimer’s disease? by Olsen, Ingar & Singhrao, Sim K
REVIEW ARTICLE
Can oral infection be a risk factor for Alzheimer’s
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Alzheimer’s disease (AD) is a scourge of longevity that will drain enormous resources from public health
budgets in the future. Currently, there is no diagnostic biomarker and/or treatment for this most common
form of dementia in humans. AD can be of early familial-onset or sporadic with a late-onset. Apart from
the two main hallmarks, amyloid-beta and neurofibrillary tangles, inflammation is a characteristic feature of
AD neuropathology. Inflammation may be caused by a local central nervous system insult and/or by
peripheral infections. Numerous microorganisms are suspected in AD brains ranging from bacteria (mainly
oral and non-oral Treponema species), viruses (herpes simplex type I), and yeasts (Candida species). A causal
relationship between periodontal pathogens and non-oral Treponema species of bacteria has been proposed
via the amyloid-beta and inflammatory links. Periodontitis constitutes a peripheral oral infection that can
provide the brain with intact bacteria and virulence factors and inflammatory mediators due to daily,
transient bacteremias. If and when genetic risk factors meet environmental risk factors in the brain, disease is
expressed, in which neurocognition may be impacted, leading to the development of dementia. To achieve the
goal of finding a diagnostic biomarker and possible prophylactic treatment for AD, there is an initial need to
solve the etiological puzzle contributing to its pathogenesis. This review therefore addresses oral infection as
the plausible etiology of late-onset AD (LOAD).
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A
lzheimer’s disease (AD) is a neurodegenerative
disease and the most common example of a
group of diseases that manifest as dementia. It is
associated with atrophy and specific neuronal death
particularly in the hippocampal region of the brain (1).
Research into AD pathogenesis has flagged two main
categories of the disease: the familial-onset presentation
accounts for around 2% of all AD cases and the sporadic
form of late-onset AD also referred to as LOAD con-
stitutes approximately 98% of the cases. LOAD displays
genetic susceptibility traits of which the well-known risk
factor is inheritance of the apolipoprotein (APOEo4)
gene allele (2) and, it appears to require an environmental
factor for disease expression. For example, a pathogen
host interaction can exacerbate neurocognition in some
elderly individuals who if in their 80 years likely
become diagnosed with LOAD (3, 4). The rationale for
this review therefore is to try to explain the etiology in the
vast proportion of LOAD cases that relies on common
risk factors. Several scientists have proposed one of these
to be peripheral infections (511) and the accompanying
systemic and local inflammatory mediators (1113). Of
these, the plausible risk from oral infection is the main
focus of this review.
Prevalence of AD
AD is a burden of longevity resulting from the superior
quality of healthcare provision for all. This factor is likely
to contribute to quadrupling of AD subjects living in our
society during the next 40 years (14). It is estimated that
by 2050 about 1314 million people are likely to suffer
from AD in the United States with a rise in the total costs
estimated to be more than $1 trillion. The odds of having
a diagnosis of AD when over 85 years of age exceed
1:3 (15). One in six people over 80 years in the United
Kingdom has dementia (16). Estimates for the prevalence
of AD in the United States indicate that more than
5 million individuals who are 65 years or older currently
suffer from AD (1, 15). About 200,000 subjects have been
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diagnosed with the early-onset familial AD form and
healthcare costs for this disease are about $200 billion
per year (1). It is clear that AD is fast becoming a major
health challenge in the United States and around the
globe that will financially drain public health budgets and
caregiver services.
Neuropathological characteristics of the
AD brain
The AD brain is characterized by several neuropatholo-
gical features of which two seminal hallmarks (Fig. 1)
arise from proteostasis of the ongoing neurodegenera-
tive processes and are essential for a definitive diagnosis
of the disease post mortem (17). One of the hallmark
proteins is made up of fibrils in the form of extracellular,
insoluble plaques and consists primarily of amyloid-beta
(Ab) (18). These peptide deposits in variable sizes depend
on the secretase enzymes (a-, b-, and Y-secretases) that
cleave it from the longer amyloid precursor protein (APP).
Initial reports suggested fibrillar Ab to be neurotoxic (19)
as it has been shown to kill all types of cells by apoptosis
induction (20). However, there are two known insoluble
fibrillar Ab amyloid peptides composed of Ab40 and
Ab42 amino-acid residues which exhibit distinct physio-
logical states within the human brain. There is a general
consensus among scientists that the larger (Ab42) peptide
is the neurotoxic form as the aging brain of cognitive
intact individuals also displays Ab plaques. However, in
the cognitively intact brain they are fewer in number and
usually of the diffuse Ab40 type that appears not to bear
any, as yet known, pathological significance. In addition,
there are the soluble monomeric, dimeric, and the multi-
meric forms of Ab (21). The relative neurotoxicity of
these isoforms remains unclear (22).
More recently, the fibrillary forms of the Ab(40/42)
peptides released in the AD brain were also recognized as
‘defensin’ or innate immune defense molecules that act to
protect the host against infection (23). For example, both
of the aforementioned amyloidogenic peptides can bind
to bacterial membranes and in that way lyse bacterial
cells. Although Ab is acting as an antimicrobial peptide
(AMP), it may be a part of the brain’s ancient/modern
innate immune defense mechanism. AMPs are potent,
broad-spectrum, pore-forming agents targeting Gram-
negative and Gram-positive bacteria, enveloped viruses
and protozoans (23), thereby supporting the hypothesis
that AD has an infectious origin.
Furthermore, the senile plaques (Ab42) are recognized
as triggers that stimulate activation of microglial cells and
initiate local immune responses (24). Activated microglia
are the most important contributors of inflammation in
the central nervous system (CNS) (25). They secrete a
number of pro-inflammatory cytokines (2426) and re-
cognize pattern-associated molecular patterns (PAMPs)
on bacteria and their cellular debris (2730) in response
to CNS infection.
The other pathological characteristic of AD is an ac-
cumulation of intracellular hyperphosphorylated tau and
heat shock proteins constituting the neurofibrillary tangles
(NFTs). Hyperphosphorylated tau protein alters the
polymerization and stability of microtubules compromis-
ing their function (31). NFTs in AD reflect the severity
of disease; however, the significance of pathogenhost
interaction to the occurrence of NFTs in the AD brain
is poorly understood. Current genetic evidence is point-
ing to aberrant innate immune responses (32, 33) and
cholesterol lipid genes (34) having greater significance in
AD pathogenesis. A dysfunctional immune system and
predisposition to hyperlipidemia also support the role of
reduced blood flow due to the vascular lesions and in-
flammation, Ab deposition and microorganisms in AD.
In advanced AD pathology, synaptic dysfunction is
another structural defect associated with a decline in
memory (3537). Although a circular argument, malnu-
trition plays a role in the gradual loss of synapses and
fewer teeth during life is a known risk factor for AD (38).
Neurons are capable of responding to injury by expres-
sing multiple neurotransmitters. In AD, selective loss
of cholinergic neurons in the basal forebrain (39) also
correlates with the loss of cognitive function (18, 35).
The amyloid cascade hypothesis
Several hypotheses have been advanced regarding the
development of AD. The amyloid cascade hypothesis serves
as a model particularly for the familial form of AD (40)
which is a disease caused by mutations involving the
amyloid-b protein precursor, located on chromosome
21 and presenilins 1 and 2 on chromosomes 14 and 1,
respectively, that enhance the APP gene processing toward
Ab deposition (41, 42). The model, which was first pro-
posed by Glenner and Wong (43), maintains that the
neurodegenerative disease is due to an imbalance between
NFT
x10
x40
Fig. 1. The pathological hallmarks of AD, numerous extra-
cellular amyloid-Ab plaques and intra-neuronal neurofibril-
lary tangles (NFTs). Although there are several NFTs, only
one is picked out in boxes at 10 and 40 objective lens
magnification.
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the generation and clearance of Ab. Genome-wide asso-
ciation studies (GWAS) highlighted the complement
receptor 1 (CR1) gene playing a role in AD pathogenesis
(44). One recognized role of CR1, a membrane-bound
regulatory protein, is its ability to bind C3b opsonins
(Fig. 2). It is abundantly expressed especially on ery-
throcyte membranes and as such participates in immune
complex clearance by transporting waste to the liver and
the spleen. As the CR1 gene is a risk factor for LOAD,
this suggests loss of function as a possibility for the de-
fective clearance of Ab in the brain. Other tentative
explanations suggest variation in CR1 protein isoforms
(longer and shorter forms) (45), whereby the longer form
is less involved in the disease process via its ability to bind
more C3b and facilitate more effective clearance of Ab
in the brain (46). This is a process that inevitably fails
favoring disease expression with more Ab proteostasis
buildup and complement pathway activation. The amy-
loid hypothesis has been modified several times, particu-
larly due to the finding that soluble oligomers of Ab may
contribute to early preclinical stages of the disease that
initiate the cascade leading to synaptic dysfunction,
atrophy, and neuronal loss (47).
The inflammatory hypothesis
The intrinsic model
Currently, there are two models of the inflammatory hypo-
thesis of AD, an intrinsic and an extrinsic. The intrinsic
inflammation model accounts for the intact ‘bloodbrain
barrier’ (BBB) restricting entry of neurotoxic immune mole-
cules and systemic lymphocytes to the brain. As a con-
sequence, the brain glial cells are able to generate a local
and complete innate immune system when challenged by
foreign agents (26, 4850). Historically, neuroinflamma-
tion has largely been viewed as being a downstream con-
sequence of the amyloid hypothesis, whereby the presence
of amyloidogenic peptides results in the activation of
microglia initiating pro-inflammatory cascades and the
release of potentially neurotoxic substances resulting in
degenerative changes in neurons. GWAS now implicates
innate immune genes (44, 51) as being a risk factor and
supports a primary role for the inflammatory elements of
AD pathology via inappropriate activation of the com-
plement system (5254) in association with Ab plaques
and NFTs (55).
The extrinsic model
The extrinsic model accounts for communication of the
glial cells with the immune challenges presented via the
blood vascular system using the circumventricular organs
and the choroid plexus that are devoid of the BBB (56).
The cells from this region of the brain are fully equipped
with the CD14 receptor and the toll-like receptor 4 (TLR
4) to recognize LPS from the peripheral blood circulation
(27, 28). Hence, elements of systemic infections such as
those originating from Gram-negative, highly virulent
oral pathogens, bronchopneumonia and urinary tract
infections (3, 4, 7, 57, 58) reach all organs including the
CNS. Bacterial products entering the bloodstream trigger
the innate immune responses of host cells via pattern
recognition receptors (PPR) and TLRs that alert local
and distant cells to the infectious threat by secreting im-
mune mediators (cytokines) to confine and defeat the
foreign agents. Increased risk of dementia in the elderly
following multiple infectious episodes has been reported
(4). In addition, systemic infections appear to contribute
toward delirium in some clinically diagnosed AD patients
and such episodes can exacerbate a premorbid cogni-
tive status (3). Holmes et al. (3, 57) proposed that since
cytokines are primary mediators released by the host to
defend against infection, such secondary stimuli (IL-1b
and TNF-a) may mediate their effect on the brain and
indirectly contribute to cognitive decline.
Non-oral bacteria related to AD
Honjo et al. (59) using Bradford Hill’s criteria for as-
sessing the relationship between bacteria and disease
found Chlamydophila pneumoniae to be a likely infectious
agent related to the pathogenesis of AD. Maheshwari and
Eslick (60) reported a strong correlation between C.
pneumoniae and AD, and according to Shima et al. (61)
C. pneumoniae is currently the most plausible of all
infectious agents proposed to be involved in AD. Lim et al.
(62) suggested that the pro- and chronic inflammatory
states in AD pathogenesis may in part be due to C.
pneumoniae infection of monocytes. C. pneumoniae anti-
bodies from typical intracellular and atypical C. pneumoniae
Fig. 2. Immunofluorescence labeling (green dots) of hippo-
campal CA neurons opsonized by iC3b following mono-
infection with P. gingivalis at 24 weeks of APOo gene
knockout (ApoE/ ) mice. This is indirect evidence of an
oral infection having affected the host’s brain.
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antigens have been identified both in the frontal and
temporal cortices of brains from AD patients (63).
Amyloid deposit and NFTs were detected in the same
regions in apposition to one another suggesting that C.
pneumoniae infection is involved in the development of
AD pathology.
Using various techniques, Balin et al. (9) found C.
pneumoniae in 8090% of LOAD brain tissue specimens.
C. pneumoniae infection was correlated with the APOEo4
allele expression. The same researchers subsequently
demonstrated that astroglia, microglia, neurons, endo-
thelial cells, and monocytes in the LOAD brain are
permissive to this bacterium. The mechanisms of patho-
genesis differ between actively and persistently infecting
chlamydiae and it is in the persistent state that these
organisms cause chronic disease (64, 65). C. pneumoniae
was cultured from two AD brain samples after one or
two passages in HEp-2 cells (66). Interestingly, the study
indicated that brain isolates were more related to respi-
ratory than to vascular/atheroma strains of C. pneumoniae.
This suggested that C. pneumoniae infection of the brain
was secondary to bronchopneumonia and at the end
stages of LOAD.
It has been suggested that the phages phiCPAR39 and
phiCPG1, associated with C. pneumoniae, may enter
mitochondria of the bacterial host and work as slow
viruses initiating AD (67). These authors hypothesized
that mitochondrial recruitment by C. pneumoniae phages
may be the primary initiating event in the pathogenesis of
neurodegenerative disorders.
In a meta-analysis based on 25 relevant, primarily
case-control studies, Maheshwari and Eslick (60) found
a statistically significant association between AD and
detectable evidence of infection caused by C. pneumoniae
or spirochetes. They reported over a 10-fold increased
occurrence of AD when there was evidence of spirochetal
infection (OR: 10.61; 95% CI: 3.3833.29) and over a
fourfold increased occurrence of AD with a conservative
risk estimate (OR: 4.45; 95% CI: 2.338.52). There was a
fivefold increase in occurrence of AD with C. pneumoniae
infection (OR: 5.66; 95% CI: 1.8317.51). Accordingly, a
strongly positive association between bacterial infection
and AD was shown for both types of bacteria, but it was
strongest for spirochetes.
It is generally accepted that the syphilis spirochete
Treponema pallidum can cause chronic neuropsychiatric
disorders including dementia as well as other neurode-
generative disorders (11). T. pallidum causes brain atrophy
and Ab deposition in the atrophic form of general paresis
(68, 69) and is a strong indication for involvement of
spirochetes in AD pathogenesis. Chronic diseases such
as syphilis are frequently associated with deposition of
amyloid (68, 69). Amyloid is an integral component of
spirochetes which may contribute to amyloid deposition
in AD (70). Spirochete accumulation in the cerebral
cortex in the context of syphilis will also lead to for-
mation of senile plaques, NFTs, and granulovacuolar
degeneration (71).
Miklossy (68, 69) analyzed data on the ability of spi-
rochetes to induce pathological and biological hallmarks
of AD in vitro following Koch’s and Hill’s postulates and
demonstrated a plausible causal relationship between
neurospirochetosis and AD. The data revealed a statisti-
cally significant association between spirochetes and
AD (p1.51,017, OR20, 95% CI860, N247).
When mammalian cells were exposed to spirochetes, the
pathological and biological hallmarks of AD were re-
produced in vitro (68, 69). Historical observations sup-
ported the conclusion that chronic spirochetal infections
can cause dementia and reproduce the neuropathological
hallmarks of AD (72). According to Miklossy (72), these
observations represent further evidence in support of a
causal relationship between various spirochetal infections
and AD.
Another spirochete also implicated in AD is Borrelia
burgdorferi, the causative agent of Lyme disease which is
transfected to humans via tick vectors. There are great
similarities in the clinical and pathological manifestations
of syphilis and Lyme disease (72, 73). The occurrence
of B. burgdorferi in the brains of AD patients was first
reported by MacDonald and Miranda (74) and was
confirmed later by MacDonald (75, 76), Riviere et al.
(5), and Miklossy et al. (77). Interestingly, Bu et al.
(78) found that the infectious burden consisting of B.
burgdorferi, C. pneumoniae, Helicobacter pylori, cytome-
galovirus,and herpes simplex type-1 (HSV-1) is associated
with AD. In contrast, Gutacker et al. (79) and Pappolla
et al. (80) found no evidence of an association between
B. burgdorferi and AD.
Among other bacterial species, H. pylori (monoinfec-
tion) has been found to be related to AD (59). These
authors suggested that AD pathology can be initiated
and exacerbated by some microorganisms with inflam-
matory and oxidative responses which may affect the
brain continuously and gradually over time. However,
the H. pylori status was not associated with AD in a
study from Japan, probably due to the high prevalence
of the organism in controls (81). This was refuted by
Kountouras et al. (82) who had previously found that
successful eradication of H. pylori infection was associated
with significantly lower mortality risk in AD patients
[HR (95% Cl)0.287 (0.1140.725), p0.008] (83).
Oral bacteria related to AD
The oral cavity harbors an impressive range of bacterial
phylotypes (84). Molecular identification methods have
detected close to 900 different predominant bacterial
species of which 35% cannot yet be cultured (85). The
oral microbiome profiles appear to be individualized
(86), meaning that bacterial microbiomes can vary both
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qualitatively and quantitatively between individuals, although
there are also significant overlaps. Each individual can
harbor up to 200 different bacterial taxa in their mouth
and there is a large variation in the microbiota in dif-
ferent oral sites (84, 87). Furthermore, the composition
of the oral microbiota irrespective of being indigenous
or pathogenic in the oral cavity keeps changing in view
of major oral diseases (caries, gingivitis, aggressive and
chronic periodontitis, periodontal-endodontic lesions, peri-
implantitis, and mucositis) (8894). Particularly, plaque-
induced oral diseases such as periodontitis are associated
with a change in the oral microbiota. There is a pre-
dominance of anaerobic bacteria in the oral cavity. Many
of the major periodontal microorganisms are anaerobic,
e.g. Porphyromonas gingivalis, Treponema denticola, and
Tannerella forsythia. The abundance of anaerobes tends
to increase with the development of plaque-induced oral
diseases.
Periodontal bacterial pathogens are related to AD
Major pathogens of chronic periodontitis such as P.
gingivalis, T. forsythia, and T. denticola are implicated
in the development of several inflammatory diseases at
remote organ sites. Except for T. forsythia, all three of the
above-named organisms of which T. denticola represents
a spirochete, have been found in the AD brain (5, 8).
Spirochetes are strongly neurotropic. They can spread
along nerve fibers and via lymphatics (67, 68) and have
been detected in the trigeminal nerve and trigeminal
ganglia (95). Spirochetes and their antigens as well as DNA
have been found associated with AD and are strongly
implicated as the causative agents leading to dementia
(68, 69). In 14 studies, spirochetes were detected in AD
by different authors in different laboratories and coun-
tries by means of different techniques (for reviews see
Miklossy (68, 69)). Riviere et al. (5) demonstrated the
presence of seven different oral Treponema species in 14
out of 16 AD brain specimens (Fig. 3). Spirochetes were
even cultivated from the brains of AD patients indicating
that they were viable in the brain (67, 68, 77). Miklossy
suggested a co-infection by several spirochetes in AD in-
cluding the oral varieties (T. socranskii, T. pectinovorum,
T. denticola, T. medium, T. amylovorum, and T. maltophilum)
as demonstrated by Riviere et al. (5). Spirochetes repro-
duced the biological and pathological hallmarks of AD
after exposure of mammalian neuronal and glial cells in
organotypic cultures (68, 69).
It was demonstrated that LPS from periodontal bac-
teria can access the AD brain during life while detection
in corresponding controls, with equivalent or longer
postmortem interval was absent (8). This study supports
the literature on elevated antibodies to periodontal
disease-associated bacteria such as P. gingivalis, being
found in AD patients (7). Furthermore, in 2,355 people
60 years and over, the third NHANES study found
associations between periodontitis and cognitive impair-
ment and between measures of immunoglobulin to P.
gingivalis and cognitive test performance (96, 97). In this
study, all participants were cognitively intact at baseline.
Those who went on to develop AD had higher levels of
serum antibodies to periodontal pathogens at baseline.
The study suggested a temporal relationship in that the
periodontal disease came before AD.
Other important periodontal pathogens related to AD
are Fusobacterium nucleatum and Prevotella intermedia.
In the NHANES study, antibody levels to these organ-
isms were significantly increased (a0.05) at baseline
serum in patients with AD compared to that in controls
(97). The results were significant after controlling for
baseline age, Mini-Mental State Examination score, and
allele APOEo4 status. Noble et al. (98) found that a high
anti-Actinomyces naeslundii titer (640 ng/ml, present in
10% of the subjects) was associated with increased risk
of AD (HR2.0, 95% CI: 1.13.8). This association was
stronger after adjusting for other significant titers
(HR3.1, 95% CI: 1.56.4) and confirmed that period-
ontal pathogens may be associated with AD.
Possible consequences to the brain carrying oral
bacterial pathogens
The fact that inflammation is sustained in the AD brain
suggests that local immunogenic hallmark proteins and/
or peripheral infections are key perpetrators. This is
supported by reports highlighting microorganisms and
their toxic products as well as DNA in brain tissue of AD
patients and experimental animals (see below). Bacteria
activate pathways that include the integrin receptor
CR3 (CD11b/CD18) and TLR signaling (99) and the
Fig. 3. Section of pons area of Alzheimer’s disease brain
from an 84-year-old female subject (from Ref. (5) with
permission), demonstrates metabolically active Treponema
pectinovorum oral bacteria (arrows) stained dark blue
following immunostaining with anti-T. pectinovorum using
the avidinbiotin peroxidase method.
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complement cascade (100). The NF-kB signaling path-
way for cyto/chemokine release (TNF-a, IL-8) (101)
produces free radicals, triggers nitric oxide and apoptosis
(102). The oral cavity, lungs, and gastrointestinal and
urinary tracts are plausible sources of brain microorgan-
isms. The likely passage of the microorganisms of interest
from their original sites to the brain is described below.
Infections with spirochetes can cause cerebral hypo-
perfusion (103), cerebrovascular lesions, and a severely
disturbed capillary network (68, 69). Chronic spirochetal
infections can also induce slowly progressive dementia,
cortical atrophy, chronic inflammation, and Ab deposi-
tion, indistinguishable from that occurring in AD brains
(for reviews see Refs. 68, 69, 72). Furthermore, cultured
neuronal cells exposed to spirochetes produce Ab (104).
Spirochetes are also able to form plaque-, tangle-, and
curly fiber-like lesions (72, 105). They induce a latent and
slowly progressive infection by evading host defenses.
This promotes their survival and proliferation in the
brain by blocking the complement cascade. Spirochetes
may even survive and proliferate in hosts that are
immune-competent. Interestingly, the remarkable ability
of T. pallidum to evade clearance from the immune sys-
tem has earned it the designation ‘stealth pathogen’ (106).
The activated complement cascade following spirochete
infections (11) may be used as a non-specific marker of
CNS inflammation. Spirochetehost interactions initiate
and sustain chronic inflammation triggering various
immune responses that activate the innate and adaptive
immune system, free radical production, apoptosis, and
amyloid deposition typically seen in AD brains (107).
P. gingivalis has been designated as one of the ‘key-
stone’ periodontal pathogens because it is able to establish
and maintain the periodontal disease-associated ‘inflam-
mophilic’ microbiota (108). It is able to perform this task
as it possesses an awesome variety of virulence factors,
recently reviewed by Singhrao et al. (109), to evade the
host immune defenses, thus serving two major functions:
initial survival of P. gingivalis itself via a sustainable in-
flammatory milieu and sustainment of nutritional sources
by eliminating microbial competitors (108).
The P. gingivalis endotoxin LPS demonstrates differ-
ences in the number of phosphate groups together with
both the amount of lipid A fatty acids and their specific
position. The presence of multiple lipid A structures
makes it more difficult for the innate host responses to
recognize the molecule thereby aiding the virulence of P.
gingivalis (110). The consequences of finding P. gingivalis
LPS in the host’s body, e.g. the brain (8), include priming
of immune cells for differential activation of the TLR-
mediated NF-kB signaling pathway (111) leading to
cytokine liberation, complement activation, and main-
tenance of intracerebral inflammation.
P. gingivalis evades circulating phagocytes by adhering
to erythrocytes (112). An active invasion of P. gingivalis
and infection-induced complement activation with by-
stander neural injury was detected in the brains of
ApoE/ mice (113). This supported previous notions
that bacterial infections can contribute to the develop-
ment of AD pathology via mechanisms involving acute-
phase proteins such as cytokines and the complement
cascade where neurons would be attacked.
Oral virus related to AD
Herpes simplex virus (HSV) is present in more than
70% of the population after 50 years of age (114116).
It persists latently in the peripheral nervous system and
is periodically reactivated. Characteristically, HSV-1 has
been designated as the enemy within (10). Herpes viruses,
including Epstein-Barr virus and cytomegalovirus, are
found in high copy counts in aggressive periodontitis, and
may interact synergistically with periodontopathic bac-
teria in the pathogenesis of this disease (117). Periodontal
infections activated by Herpes virus may impair local
host defenses and thus increase the aggressiveness of
resident periodontopathic bacteria. The bacteria, in turn,
may augment the virulence of the herpes viruses.
High proportions of viral-associated proteins in amy-
loid-containing plaques and/or NFTs corroborate with
the involvement of HSV-1 in AD pathology (118). Notably,
De Chiara et al. (119) reported an association between
Ab accumulation in the brain and HSV infection. Itzhaki
et al. (120) suggested that not only does HSV-1 produce
the main components of amyloid plaques and NFTs (i.e.
Ab and hyperphosphorylated tau), but it also interferes
with the autophagic events that prevent degradation of
these proteins and eventually leading to their accumula-
tion in the AD brain. Furthermore, in vitro and in vivo
investigations in murine models following HSV-1 infec-
tions demonstrated Ab accumulation (121).
A number of scientists have suggested that there
is an imbalance between production and clearance of
b-amyloid in the brain, a premise first proposed by
Wisniewski et al. (122) based on the discovery of soluble
species of this protein and later confirmed by Zlokovic
et al. (123). It is now widely accepted that defective
clearance of this protein is a hallmark of AD brains
leading to its accumulation in the form of insoluble
Ab40/42 plaques. Although HSV and cytomegalovirus
have been detected in the brains of older adults with and
without AD (124126), HSV-1 viral DNA is present in a
higher proportion of AD patients (127). It is particularly
seen in the temporal and frontal cortices which are the
brain regions that are most damaged in AD (128, 129).
The relevance of this association is still under investiga-
tion; however, a plausible role for the HSV-1 viral DNA
could be associated with the plaque maturation process.
Jamieson et al. (127) found that the virus was absent in
the brains of most young people, probably because it
enters the brain during old age either with immune
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senescence (130) or the virus itself is initially responsible
for weakening host’s immune defenses. This latter ex-
planation is likely and is supported by us and others (131).
HSV-1 is a strong risk factor for AD in the brains
of those with the APOEo4 allele (125, 132). This virus is
not only a dormant passenger but can also persist in the
latent form in neurons or replicate at a very low level in
neuroglia (133). During persistence, it may release toxic
products continuously and induce pro-inflammatory cyto-
kines at low levels which become an additional burden
to a host already challenged by age, poor diet, restricted
exercise as well as any genetic susceptibilities. Itzaki and
Wozniak (10) suggested that stress or peripheral infection
can reactivate the virus periodically from latency in the
brain. This may cause an acute but presumably localized
infection, and subsequent damage modulated by the
APOo gene can lead to formation of Ab plaques and
NFTs.
The presence of anti-HSV IgM, a sign of reactivated
infection, almost doubled the risk for AD while anti-HSV
IgG did not influence the risk (134). Kobayashi et al.
(135) suggested that the anti-HSV-1 Ig antibody avidity
index could be a useful biomarker for early diagnosis of
amnestic mild cognitive impairment, which is prodromal
to AD, as well as for AD sufferers.
Reactivation of HSV seropositivity is highly correlated
with incident-AD (136). Letenneur et al. (136) speculated
that AD pathology starts many years before frank
dementia and recurrent reactivation of HSV can act as
a potent stimulus to brain microglia, increasing cytokine
levels, and triggering a positive feedback cycle leading to
increasing accumulation of neurohistopathological changes.
In other words, infection, followed by local CNS inflam-
matory reaction is the likely primary stimulus whereas
proteostasis is a consequence of the primary event lead-
ing to the development of AD.
Hill et al. (137) suggested a role for HSV-1-induced
miRNA-146a in the evasion of HSV-1 from the comple-
ment system which is a major first-line host defense
mechanism, and the activation of key elements in the
arachidonic acid cascade known to contribute to AD-
type neuropathological changes.
Oral yeasts related to AD
Oral yeast infection represents a secondary opportunistic
infection particularly involving Candida albicans, but
increasingly non-albicans species, e.g. Candida glabrata.
With a growing population of elderly, severe systemic
fungal infections have increased dramatically in this age
group during the last 30 years (138, 139). Oral yeasts can
be found in periodontal pockets, in root canals, on the
mucosae and underneath dentures (denture stomatitis)
(140142). Denture stomatitis is prevalent in elderly wear-
ing dentures that are heavily contaminated with yeasts
which can be a source of systemic mycosis. Disseminated
mycoses have recently been reported in AD patients
(143, 144). Fungal molecules including proteins and
polysaccharides [(1,3)-b-glucan] were detected in periph-
eral blood serum, and fungal proteins and DNA were
demonstrated by PCR in brain tissue of AD patients.
Chitin-like fungal structures have also been found in the
AD brain (145) and chitinase activity has been proposed
as a powerful biomarker of AD (146). In AD brains,
cytoplasmic material in a small number of cells was tar-
geted by antibodies with immunoreactivity to yeast cells
(147). These findings were consistent with the idea that
neurons can be infected by fungi. Interestingly, antifungal
treatment reversed the clinical symptoms of some AD
patients (148, 149).
How do oral microorganisms reach the brain?
Blood stream dissemination
The most likely pathway for dissemination of oral micro-
organisms to the brain is through the blood stream (150).
Dental treatment as well as brushing, flossing, chewing,
and use of tooth picks in a patient with periodontitis will
release a bacteremia (151). This can occur several times
during the day and has been estimated to last for up to
3 hours for oral bacteria (152). The bacteremia is usually
contained by immune cells of the body. However, in
people with reduced immune defense, e.g. older indivi-
duals, bacteria may localize to crevices of the oral cavity
and vascular channels (150).
The bloodbrain barrier
An intact BBB prevents microorganisms in the blood
from accessing the brain. However, aging favors over-
growth of oral microorganisms, particularly anaerobic
bacteria and facultative yeasts that established earlier
in life and provoked pro-inflammatory responses that
weakened the BBB (16). Notably, magnetic resonance
imaging (MRI) confirmed loss of BBB integrity in a
mouse model of disseminated candidosis (153). Loss of
integrity allows microorganisms to spread through the
blood stream and quietly contribute in the pathogenesis
of AD. During immunosenescence, the innate immune sys-
tem gradually takes over for the acquired immune system.
This contributes to a rise in circulating pro-inflammatory
cytokines such as TNF-a (16). Indeed, pro-inflammatory
mediators can cross the BBB (3, 7, 154). APOEo4, TNF-a
and perhaps Ephrin Type-A Receptor 1 (EphA1) may
influence BBB integrity and thus be important for
penetration of bacteria, LPS, and other toxic bacterial
products as well as yeasts into the brains of AD patients
(16). APOEo4 affects the integrity of the BBB by acti-
vating the cyclophilin A matrix metalloproteinase MMP-
9 pathway (155).
It is also plausible to suggest that the permeability of
the BBB increases with age and thus promotes AD
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pathogenesis making the brain accessible to microorgan-
isms. Mice with a mutation in the APP gene which is
related to early-onset AD in humans, showed increased
permeability of the BBB and increased formation of
senile plaque as compared to that in control mice (156).
The changes increased with age.
Circumventricular organs and perivascular spaces
Circumventricular organs (permit polypeptide hypotha-
lamic hormones to leave the brain without disrupting the
BBB) are not dependent on the BBB (56) and may act as
another entry portal to the brain for bacteria (157). Poole
et al. (8) postulated that bacteria and their products may
also directly access the brain via the systemic circulation
through the perivascular spaces.
The olfactory hypothesis
The ‘olfactory hypothesis’ suggests the olfactory tract as
a potential route for pathogenic bacteria to enter the
brain and thereby trigger the production of Ab and NFTs
(158). The olfactory and trigeminal nerves are known to
be used by periodontal pathogens to bypass the BBB for
direct passage to the CNS (5, 150, 159, 160). Identifica-
tion of oral treponemes in the trigeminal ganglia supports
such a route of dissemination (5). Furthermore, spir-
ochetes may spread along the fila olfactoria and tractus
olfactorius (68, 69).
Olfactory unsheathing cells (OECs) engulf bacteria
and migrate toward TNF-a released by activated astro-
cytes (161). Therefore, OECs could be a vehicle for trans-
porting live bacteria into the brain (i.e. Trojan horse). The
olfactory bulb was the first area where NFTs and Ab
deposition were detected in the neuropathological trajec-
tory of AD in humans (162) and in mouse models of
AD (163).
Genetic, nutritional, and environmental factors
promoting AD
While early-onset AD is genetically determined, LOAD is
thought to result from interaction between genetic and
environmental factors (12). Several mutated genes are
associated with the familial AD, such as the amyloid beta
(Ab) precursor protein (AbPP) gene and the presenelin-1
(PSEN-1) and PSEN-2 gene (164166). A major risk
factor for LOAD is polymorphism in the APOo4 allele
(2). Also cytokine-related genes seem to be involved in
the susceptibility to inflammation in both LOAD (167,
168) and periodontitis (169171). Thus, polymorphisms
that increase TNF-a also increase the risk of both AD
and periodontitis (172, 173). Lambert et al. (174) found
that 20 different loci can increase host susceptibility to
AD including polymorphisms in genes associated with
interleukin-1 (IL-1) (71, 175178) and TNFa (71, 172,
179181). The APOo4 gene, which is one of these 20 loci,
is highly correlated with AD (182) but it is also a risk
factor for infection and increases the expression of
inflammatory mediators (11). Recently, genetic overlap
between AD, C-reactive protein (CRP) and plasma lipids
was demonstrated by using summary statistics from
GWAS of over 200,000 individuals (183). There may
also be interplay between genetic risk and environmental
risk factors such as toxins and or bacterial, viral and
fungal pathogens in LOAD reflecting its complex and
multifactorial etiology (1).
Diet with its content of essential B-vitamins, phospho-
lipids, and other micronutrients is important for forming
new nerve synapses (184). Nutritional deficiencies are
common both in elderly and in dementia subjects as
briefly discussed by Singhrao et al. (150).
Association between chronic periodontal
disease and AD
There is increasing evidence for an association between
chronic periodontitis and LOAD (185). Cross-sectional
and longitudinal studies have demonstrated that gingival
bleeding, loss of periodontal attachment, periodontal
probing depth, alveolar bone loss, and antibodies to
periodontal pathogens are significantly associated with
lower cognitive function and decline after adjustment for
co-variates (for a review see (12)). Acute-phase proteins,
including cytokines are possible indirect links between
periodontal pathogens and/or their virulence factors (12,
13). Elderly often show neglect of oral hygiene which can
stimulate recurrent chronic oral infection (150). This
again promotes inflammation which can lead to confu-
sion and dementia (3, 4, 154). In 152 subjects 5070 years
of age who were followed for 20 years, greater levels of
periodontal inflammation correlated with lower cognitive
levels (186). Furthermore, gingival bleeding and loss
of periodontal attachment were significantly associated
with cognitive impairment in a cohort of 5,138 people
aged 2059 years (187). In 144 nuns, those encoding
APOEo4 and who had fewer teeth experienced more rapid
cognitive decline than those with neither or either of these
risk factors (188). Clinical and epidemiological studies
showed that loss of teeth is associated with poor memory
(6, 96, 187, 189). In another study of 597 community
dwelling men followed for 32 years, tooth loss, increasing
periodontal pocket depths, and progression of alveolar
bone loss were associated with impaired cognition par-
ticularly in those over 45 years of age (190). Recently, de
Souza Rolim et al. (191) found that periodontal infec-
tions were more frequent in patients with mild AD than
in healthy subjects. Another interesting feature related
to the pathogenesis of AD is the low level of infection by
‘commensals on the loose’ (16). These ‘immuno-tolerated’
bacteria may silently multiply in sites outside of their
primary niche and an ongoing infection at their second-
ary location may have significant deleterious effects upon
the health of the elderly or demented host with an exist-
ing immunocompromised status.
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Putative treatment and prophylaxis of AD
There is no effective treatment or prophylaxis yet for
AD, but several approaches have been proposed. Efforts
in this respect are important. If we could delay onset of
dementia by only 2 years we might lower the prevalence
of AD by more than 22 million cases over the next 40
years (14). Notably, the inheritance of the APOEo4 allele
in the very old (90 ) age group appears to confer pro-
tection (192), having bypassed a period of being at risk
around 85 years of age.
If periodontal disease is implicated in AD, period-
ontitis prophylaxis could be of help. It would be interest-
ing to see if this has any effect on the initiation and
aggravation of AD but an observation period of decennia
is probably needed.
In a study of subjects with mild-to-moderate AD, a 3-
month course of doxycycline and rifampicin reduced
cognitive deterioration during a 6 months’ follow-up
interval (193). It was concluded that use of antibacterial
compounds may not have had any effect on the treatment
of C. pneumoniae but had a beneficial effect on cognitive
decline in AD (193). This might be related to prevention
or attenuation of a number of peripheral infections or
dampening down the pro-inflammatory cytokine response.
Minocycline was found to correct early, pre-plaque neu-
roinflammation and inhibit the APP cleaving enzyme
1 (BACE-1) in a transgenic model of AD-like amyloid
pathology (194). It was suggested that interfering with
inflammation could be a useful therapeutic approach in
early, pre-plaque stages of AD-like amyloid pathology.
Anti-inflammatory drugs given for at least 2 years
before the onset of dementia delayed the disease process
(195197). It may also be beneficial to combine anti-
inflammatory agents with antibacterials (193). Examina-
tion of several available non-steroidal anti-inflammatory
drugs (NSAIDs) showed that only a few of them had any
useful Ab-modifying or other activity of therapeutic use
in LOAD (for a review see (1)).
Itzhaki and Wozniak (10, 198) suggested that antiviral
therapy and perhaps vaccination against HSV-1 in early
life could be useful. If HSV-1 is implicated in AD,
vaccination could prevent the excessive accumulation of
Ab in the brain. Vaccination with mixed HSV glycopro-
teins prior to HSV infection protected against viral
latency in mouse brains (199). Also Mori (200) main-
tained that antiviral approaches including chemotherapy
and vaccination are promising for prevention and treat-
ment of AD and remaining to be validated. Furthermore,
Carter (118) suggested that vaccination or antiviral
agents and immune suppressants may be considered as
therapeutic options before or during the early stages of
AD. Interestingly, exposure of HSV-1-infected cell cul-
tures to intravenous immunoglobulin acting via anti-b-
amyloid antibodies reduced the accumulation of Ab and
phosphorylated tau (201).
Angiotensin-converting enzyme (ACE) from Stigmatella
aurantiaca may cleave the Ab peptide similar to human
ACE and may be used as a novel form of treatment against
AD (202). Furthermore, Chiarini et al. (203) maintained
that calcilytics could halt AD progression and preserve the
patients’ cortical neurons, cognitive abilities, and eventually
life if given at minimal cognitive impairment or at earlier
stages. Studies using mice suggested the use of tau aggrega-
tion inhibitors as potential drugs for the treatment of AD
and other tauopathies (204).
Resveratrol is a polyphenol present in red wine. Its
capability of directly interfering with the toxic b-amyloid
protein aggregation in AD has recently been shown (205).
Resveratrol was found to reduce Ab-induced toxicity in a
Caenorhabditis elegans model of AD by targeting specific
proteins involved in proteostasis and thereby reducing the
amount of aggregated Ab (206). This is in concert with
our previous finding that the effect of a drinking pattern
of 27 times per week reduced the risk of myocardial
infarction among men who had a history of tooth extrac-
tions due to periodontal/dental infection (207).
Potent inhibitors of Ab oligomer formation or Ab-
induced cell toxicity have proven to be attractive means
for therapeutic intervention of AD. Song et al. (208)
found that the anti-Alzheimer effects of centipedegrass,
which contains several C-glycosyl flavone constituents,
occurred through inhibition of neuronal cell death by
intervening with oligomeric Ab formation and reducing
beta-site APP cleaving enzyme 1 activity. The authors
suggested that maysin, a major flavonoid of corn silk, in
centipedegrass could be an excellent therapeutic candi-
date for the prevention of AD.
Active immunization against important domains of
Alzheimer tau eliminated tau aggregation and neurofi-
brillary pathology (209). The AD type of tau hyper-
phosphorylation was abolished in transgenic mice by
vaccination across a wide range of AD phospho-epitopes.
Kontsekova et al. (209) demonstrated that active im-
munization of rats with a tau peptide encompassing the
epitope revealed by monoclonal antibody DC8E8 led
to elimination of all major hallmarks of neurofibrillary
pathology involving a 95% reduction in the AD-type
hyperphosphorylation of tau.
Conclusions
LOAD, which is the predominant form of AD, does not
seem to have a single cause. On the contrary, a multitude
of factors may be involved and they may act in concert.
Among others, both genetic and environmental factors
may be involved. Even among microorganisms, coopera-
tion may occur since the brain can hardly differentiate
between different microbial insults which collectively
contribute capacity for enhancing inflammation. Irre-
spective of the cause, systemic inflammation may predict
the onset of dementia. Organisms such as spirochetes,
Oral microbial risk factors for Alzheimer’s disease
Citation: Journal of Oral Microbiology 2015, 7: 29143 - http://dx.doi.org/10.3402/jom.v7.29143 9
(page number not for citation purpose)
P. gingivalis, C. pneumoniae, H. pylori, Herpes simplex
type I virus, and Candida are among the prime candidate
pathogens in AD brains. In the cascade of events causing
AD, oral microorganisms may play a role, particularly
anaerobic bacteria such as treponemes, P. gingivalis,
Prevotella spp., Fusobacterium and Actinomyces, but
also facultative anaerobic Candida species. It is important
to recognize that infection can occur decades before the
manifestation of dementia. The most convincing evidence
for a causal relationship between oral bacteria and AD is
noted for spirochetes which are both neurotropic and
motile. It is likely that oral infection can be a risk factor
for AD but it is not the only one. Experiments in humans
may require long exposure time to disclose key events and
mechanisms of AD. There is, as yet, no cure for AD
despite concerted efforts and investment by industry.
Prevention of AD through long-term use of antibiotics
may be impractical and could select for resistant bacteria.
This is worrisome as the prevalence of AD and the public
expenses related to its management are expected to in-
crease greatly in the next decade.
If anaerobes of periodontitis play a major role in AD,
dental hygiene and treatment will provide the AD prophy-
laxis from an early age as periodontitis is modifiable.
However, improving oral hygiene and treating periodontal
disease in the AD patient can be challenging since patients
are often uncooperative. There is also need for training
caregivers to assist with oral care in such patients.
Vaccination against key organisms and important
domains of AD has had some beneficial effect. Also
several agents interfering directly with the pathogenesis
of AD have been tested. In order to find a cure, there is
a need for clinical diagnostic information and knowledge
of the causal agents for AD so that specific treatment
options targeting these organisms can be developed. As
for diagnostic biomarkers, increased antibody levels to
specific oral pathogens in particular to P. gingivalis may
be used as a monitoring tool years before clinical mani-
festation of AD. This is important because treatment will
probably have to start early.
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